Share on StockTwits

Analysts at Leerink Swann reduced their price objective on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from $26.00 to $24.00 in a research report issued to clients and investors on Tuesday. Leerink Swann’s price objective points to a potential upside of 40.85% from the company’s current price.

Alder Biopharmaceuticals (NASDAQ:ALDR) traded down 16.08% on Tuesday, hitting $14.30. The stock had a trading volume of 198,067 shares. Alder Biopharmaceuticals has a 52 week low of $9.50 and a 52 week high of $22.95. The stock’s 50-day moving average is $15.88 and its 200-day moving average is $15.18. The company’s market cap is $440.5 million.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Tuesday, August 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.15. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $5.00 million. During the same quarter in the previous year, the company posted ($5.27) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. Analysts expect that Alder Biopharmaceuticals will post $-1.50 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on ALDR. Analysts at Bernstein initiated coverage on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 11th. They set an “outperform” rating and a $30.00 price target on the stock. Analysts at Sanford C. Bernstein initiated coverage on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 11th. They set an “outperform” rating on the stock. Four investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $24.67.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.